E3 Ligase Ligand-Linker Conjugate

Pomalidomide-PEG2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Pomalidomide-C5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-CH2CONH-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-O-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, integrating a Thalidomide-based cereblon ligand with a linker, suitable for PROTAC synthesis.

Pomalidomide-C4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Pomalidomide-C6-I TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-CH2CONH-C2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-O-CH2CONH-CH2COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and linker used in PROTAC technology.

Pomalidomide-C4-OH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Pomalidomide-C2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Pomalidomide-C3-I is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Pomalidomide-CH2CONH-C2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Pomalidomide-PEG1-CO2H is a synthetic E3 ligase ligand-linker conjugate containing a Pomalidomide-based cereblon ligand and a 2-unit PEG linker.

(S,R,S)-AHPC-C4-NH2 hydrochloride (E3 ligase Ligand-Linker Conjugates 28) is a synthesized E3 ligase ligand-linker conjugate incorporating the (S,R,S)-AHPC based VHL ligand and a linker.

(S,R,S)-AHPC-PEG2-NH2 dihydrochloride (VH032-linker 12) is a synthesized E3 ligase ligand-linker conjugate incorporating the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker[1].

(S,R,S)-AHPC-PEG5-COOH (VH032-PEG5-COOH) is a synthetic E3 ligase ligand-linker conjugate developed for use in PROTAC technology. It consists of the (S,R,S)-AHPC based VHL ligand and a 5-unit PEG linker [1].

(S,R,S)-AHPC (VH032-NH2) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC is potential useful for the targeted degradation of the androgen receptor.

Pomalidomide-C6-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Pomalidomide-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-NH-C4-NH-Boc is a synthesized conjugate used in PROTAC technology, combining a Thalidomide-based cereblon ligand with a linker.

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines a Thalidomide-based cereblon ligand with a two-unit PEG linker for use in PROTAC technology[1].

Pomalidomide-C7-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker. Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride can be used as an immunomodulator for the treatment of cancer.

(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized conjugate consisting of an E3 ligase ligand-linker and the VH032 based VHL ligand, which is commonly used in PROTAC technology. This compound serves as a key component in the synthesis of various PROTACs, including UNC6852. UNC6852 is a bivalent chemical degrader specifically targeting EED [1].

Boc-NH-PEG3 (PROTAC Linker 10) is a PEG derivative containing a hydroxyl group and Boc-protected amino group, and is a PROTAC linker.

(S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-linker 10) is a synthesized E3 ligase ligand-linker conjugate incorporating the (S,R,S)-AHPC based VHL ligand and a linker[1].

(S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) serves as an E3 ligase ligand-linker conjugate, integrating a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. This compound is utilized in PROTAC EED degrader-1, a PROTAC that targets EED with a potency (pKD) of 9.02[1].

(S,R,S)-AHPC-Me dihydrochloride, also known as VHL ligand 2 dihydrochloride, is a chemical compound utilized in the synthesis of ARV-771. ARV-771, a BET PROTAC degrader relying on von Hippel-Landau (VHL) E3 ligase, demonstrates potent degradation of BET protein in castration-resistant prostate cancer (CRPC) cells, with a DC50 of less than 1 nM. This compound serves as the VHL ligand, specifically the (S,R,S)-AHPC-based VHL ligand, that facilitates the recruitment of von Hippel-Lindau (VHL) protein.

Pomalidomide-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

(S,R,S)-AHPC-amido-C5-acid is a chemical compound that contains a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. It can be utilized in the design of XY028-133[1].

(S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized conjugate designed for E3 ligase ligand-linker applications, combining the VH032 VHL-based ligand with a linker for PROTAC development. VH-032 acts as a selective and potent VHL/HIF-1α interaction inhibitor, with a dissociation constant (Kd) of 185 nM, offering potential in anemia and ischemic diseases research[1].

(S,R,S)-AHPC-Me is a VHL ligand based on (S,R,S)-AHPC that can be used to recruit von Hippel-Lindau (VHL) proteins. It efficiently degrades BET proteins in desmoplasia-resistant prostate cancer cells with a DC50 < 1 nM, and it can be used to synthesize ARV-771.

VHL Ligand-Linker Conjugates 17 are chemical compounds that consist of a VHL ligand specialized for the E3 ubiquitin ligase, as well as a PROTAC linker. These conjugates are utilized in the synthesis of various PROTACs, including the notable ARD-266. ARD-266 is an exceptionally effective androgen receptor (AR) PROTAC degrader[1].

(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc (VH032-O-Ph-PEG1-NH-Boc) is an E3 ligase ligand-linker conjugate, specifically designed for targeting the EED protein in PROTAC applications[1].

Thalidomide-NH-C4-NH2 TFA (compound 29c) is a conjugate consisting of an E3 ligase ligand-linker, incorporating the Thalidomide-based cereblon ligand and a linker moiety. This compound, Thalidomide-NH-C4-NH2 TFA, is utilized as a component in PROTAC BRD2/BRD4 degrader-1, which is a highly potent and selective degrader targeting BET proteins BRD4 and BRD2[1].

(S,R,S)-AHPC-Me-C10-Br is a chemically synthesized conjugate that functions as a ligand-linker for E3 ligases. This compound incorporates a VHL E3 ligase linker and MS432, derived from the MEK1/2 inhibitor PD0325901[1].

(S,R,S)-AHPC-C4-NH2 dihydrochloride is a chemically derived E3 ligase ligand-linker conjugate, consisting of the (S,R,S)-AHPC VHL ligand and a linker specifically designed for EED-Targeted PROTAC[1].

Thalidomide-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET[1].

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride is a chemical compound that has been synthesized as an E3 ligase ligand-linker conjugate. This compound incorporates a cereblon ligand derived from Thalidomide and a 3-unit PEG linker. It is specifically designed for use in PROTAC technology, which utilizes small molecules to induce protein degradation [1].

Thalidomide-O-amido-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from Thalidomide with a linker. It is commonly employed in the synthesis of PROTACs[1].

Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology[1].

Thalidomide-O-amido-C8-NH2 hydrochloride is a synthetic conjugate of an E3 ligase ligand-linker, which combines a cereblon ligand derived from Thalidomide and a linker. It can be utilized in the synthesis of PROTACs[1].

Thalidomide-NH-C10-COOH (compound 6b) is a synthetic E3 ligase ligand-linker conjugate. This compound combines the Thalidomide-based von Hippel-Lindau (VHL) ligand with a linker commonly employed in PROTAC technology. [1]

Thalidomide-O-PEG2-propargyl (E3 Ligase Ligand-Linker Conjugates 32) is a chemical compound that has been synthesized as a conjugate of an E3 ligase ligand and a linker. It incorporates the cereblon ligand based on Thalidomide, along with a 2-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes ligand-induced protein degradation [1].

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-O-amido-PEG-C2-NH2 hydrochloride can be used in the synthesis of PROTACs.

Thalidomide-NH-C6-NH2 is a synthetic conjugate compound designed as an E3 ligase ligand-linker. It consists of a Thalidomide-based cereblon ligand linked to a specific linker utilized in PROTAC technology[1].

Thalidomide-O-amido-PEG3-C2-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand based on Thalidomide and a 2-unit PEG linker for use in PROTAC technology[1].

(S,R,S)-AHPC-PEG3-NH2 hydrochloride (E3 ligase Ligand-Linker Conjugates 5) is an E3 ligase ligand-linker conjugate incorporating the (S,R,S)-AHPC-based VHL ligand and 3-unit PEG linker.

Pomalidomide-PEG3-CO2H (Thalidomide-NH-PEG3-propionic acid) is a synthesized E3 ligase ligand-linker conjugate. Pomalidomide-PEG3-CO2H incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

LC3-mHTT-IN-AN2 (5,7-Dihydroxy-4-phenylcoumarin) is found in the plant Passiflora serratodigitata with the antibacterial activity.